Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 22670179)

  • 1. Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma.
    Xie H; Lin J; Thomas DG; Jiang W; Liu X
    Int J Clin Exp Pathol; 2012; 5(4):347-55. PubMed ID: 22670179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma.
    Xie H; Jiang W; Jiang J; Wang Y; Kim R; Liu X; Liu X
    Cancer; 2013 Jan; 119(1):173-81. PubMed ID: 22736490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.
    Maréchal R; Bachet JB; Mackey JR; Dalban C; Demetter P; Graham K; Couvelard A; Svrcek M; Bardier-Dupas A; Hammel P; Sauvanet A; Louvet C; Paye F; Rougier P; Penna C; André T; Dumontet C; Cass CE; Jordheim LP; Matera EL; Closset J; Salmon I; Devière J; Emile JF; Van Laethem JL
    Gastroenterology; 2012 Sep; 143(3):664-674.e6. PubMed ID: 22705007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Implications of Expression Profiling for Gemcitabine-Related Genes (hENT1, dCK, RRM1, RRM2) in Patients With Resectable Pancreatic Adenocarcinoma Receiving Adjuvant Chemotherapy.
    Sierzega M; Pach R; Kulig P; Legutko J; Kulig J
    Pancreas; 2017; 46(5):684-689. PubMed ID: 28196013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer.
    Kim R; Tan A; Lai KK; Jiang J; Wang Y; Rybicki LA; Liu X
    Cancer; 2011 Jul; 117(14):3126-34. PubMed ID: 21264835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: implications for adjuvant treatment.
    Fisher SB; Patel SH; Bagci P; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Maithel SK
    Cancer; 2013 Jan; 119(2):445-53. PubMed ID: 22569992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High expression of survivin is prognostic of shorter survival but not predictive of adjuvant gemcitabine benefit in patients with resected pancreatic adenocarcinoma.
    Xie H; Jiang W; Xiao SY; Liu X
    J Histochem Cytochem; 2013 Feb; 61(2):148-55. PubMed ID: 23124118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL17RB expression might predict prognosis and benefit from gemcitabine in patients with resectable pancreatic cancer.
    Song Y; Ji B; Jiang CX; Chen ZM; Yao NH; Mukaida N; Huang H
    Pathol Res Pract; 2019 Dec; 215(12):152650. PubMed ID: 31585811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphatic invasion is an independent prognostic factor in pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy with gemcitabine or S-1.
    Aoyama T; Murakawa M; Katayama Y; Shiozawa M; Ueno M; Morimoto M; Yoshikawa T; Rino Y; Masuda M; Morinaga S
    Hepatogastroenterology; 2015; 62(138):472-7. PubMed ID: 25916085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection.
    Nakagawa N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
    Surgery; 2013 Apr; 153(4):565-75. PubMed ID: 23253379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma - A pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials.
    Kurreck A; Weckwerth J; Modest DP; Striefler JK; Bahra M; Bischoff S; Pelzer U; Oettle H; Kruger S; Riess H; Sinn M
    Eur J Cancer; 2021 Jun; 150():250-259. PubMed ID: 33940349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study.
    Sinn M; Sinn BV; Striefler JK; Lindner JL; Stieler JM; Lohneis P; Bischoff S; Bläker H; Pelzer U; Bahra M; Dietel M; Dörken B; Oettle H; Riess H; Denkert C
    Ann Oncol; 2014 May; 25(5):1025-32. PubMed ID: 24562449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy.
    Fisher SB; Fisher KE; Patel SH; Lim MG; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Farris AB; Maithel SK
    Cancer; 2013 Jan; 119(2):454-62. PubMed ID: 22760605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.
    Versteijne E; Suker M; Groothuis K; Akkermans-Vogelaar JM; Besselink MG; Bonsing BA; Buijsen J; Busch OR; Creemers GM; van Dam RM; Eskens FALM; Festen S; de Groot JWB; Groot Koerkamp B; de Hingh IH; Homs MYV; van Hooft JE; Kerver ED; Luelmo SAC; Neelis KJ; Nuyttens J; Paardekooper GMRM; Patijn GA; van der Sangen MJC; de Vos-Geelen J; Wilmink JW; Zwinderman AH; Punt CJ; van Eijck CH; van Tienhoven G;
    J Clin Oncol; 2020 Jun; 38(16):1763-1773. PubMed ID: 32105518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer.
    Deplanque G; Demarchi M; Hebbar M; Flynn P; Melichar B; Atkins J; Nowara E; Moyé L; Piquemal D; Ritter D; Dubreuil P; Mansfield CD; Acin Y; Moussy A; Hermine O; Hammel P
    Ann Oncol; 2015 Jun; 26(6):1194-1200. PubMed ID: 25858497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer.
    Drouillard A; Puleo F; Bachet JB; Ouazzani S; Calomme A; Demetter P; Verset G; Van Laethem JL; Maréchal R
    Br J Cancer; 2016 Nov; 115(10):1245-1252. PubMed ID: 27755532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma.
    Oba A; Ban D; Kirimura S; Akahoshi K; Mitsunori Y; Matsumura S; Ochiai T; Kudo A; Tanaka S; Minoru T
    J Hepatobiliary Pancreat Sci; 2016 Aug; 23(8):480-8. PubMed ID: 27247050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas.
    Itoi T; Sofuni A; Fukushima N; Itokawa F; Tsuchiya T; Kurihara T; Moriyasu F; Tsuchida A; Kasuya K
    J Gastroenterol; 2007 May; 42(5):389-94. PubMed ID: 17530364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine.
    Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
    Oncogene; 2004 Feb; 23(8):1539-48. PubMed ID: 14661056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unresectable pancreatic ductal adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting outcomes of patients treated with chemotherapy.
    Cheng SH; Cheng YJ; Jin ZY; Xue HD
    Eur J Radiol; 2019 Apr; 113():188-197. PubMed ID: 30927946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.